Dr. Bey is an Assistant Professor in the School of Pharmacy and a member of the Sara Crile Allen and James Frederick Allen Lung Cancer Program in the WVU Cancer Institute. His interests include developing novel therapeutics for treatment of lung cancer with a focus on genes that regulate oxidative stress.
Case Comprehensive Cancer Center (Case Western Reserve University)
Simmons Comprehensive Cancer Center (The University of Texas South Western Medical Center at Dallas)
Cleveland Clinic Foundation (Department of Cell Biology)
Cleveland State University (Cell Regulatory Biology Program)
Clarion University of Pennsylvania (B.S. Biology)
Sara Crile Allen and James Frederick Allen Lung Cancer Program
Lung cancer is the leading cause of cancer related deaths in the U.S. and throughout the world. Included among the varying reasons for poor prognosis for lung cancer patients are: the fact that early screening methods are not a standard of care, ineffective therapeutic strategies, and our limited knowledge of pathways that control the transition of normal lung epithelial cells to malignant and invasive lung cancer cells. For example, oxidative stress has been implicated in mutagenic transformation of normal lung epithelial cells. However, the role that oxidative stress regulators play in this process is poorly understood.
Nrf2 is a transcription factor that is activated when cells are confronted with oxidative stress. It then promotes the induction of a variety of cytoprotective genes, which are often elevated in lung tumors vs normal lung epithelial cells. Thus, these cytoprotective genes are hypothesized to play pivotal roles in regulating oxidant stress levels in normal lung and lung tumor cells, as well as their respective microenvironments.
We will use both in vitro and in vivo models to delineate the specific roles that Nrf2 activated genes play in the process of normal lung epithelial transformation, malignant lung tumor cell proliferation and metastases. In addition, we will focus on finding the therapeutic advantages of targeting oxidative stress regulators. Finally, we will also investigate chemotherapies that synergize with ionizing radiation for effective treatment of lung cancers.